New Options for Metastatic Breast Cancer

Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
Clinical journal of oncology nursing (Impact Factor: 0.91). 02/2009; 13(1):11-8. DOI: 10.1188/09.CJON.S1.11-18
Source: PubMed


Patients with advanced breast cancer are living longer and receiving multiple lines of chemotherapy; however, they eventually develop resistance to the agents. Two more agents have been approved for the treatment of breast cancer and will provide additional treatment options for such patients. Ixabepilone represents a new class of cytotoxic chemotherapy called the epothilones. Ixabepilone was approved for use as a single agent for the treatment of metastatic breast cancer resistant to taxanes, anthracyclines, and capecitabine, as well as in combination with capecitabine for disease refractory to taxanes and anthracyclines. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, was approved for first-line treatment of HER2-negative metastatic breast cancer in combination with paclitaxel. Understanding the efficacy, toxicity, and administration of the agents is crucial for oncology nurses to optimally educate and treat patients with advanced breast cancer.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we evaluated a high surface area fractional precipitation process to achieve the effective purification of paclitaxel, an anticancer agent, from plant cell cultures. Fractional precipitation experiments were performed by increasing the surface area per working volume (S/V) to 0.428/mm using a variety of ion exchange resins. When the cation exchange resin Amberlite IR 120 H was used, the highest purity (>85%) and yield (>80%) of paclitaxel could be obtained in the shortest fractional precipitation time (within 6 h). Use of an ion exchange resin resulted in the production of smaller paclitaxel precipitates since it inhibited the growth of particles. When Amberlite IR 120 H in particular was used, paclitaxel particles were 2 ∼ 3 times smaller (less than 30 μm radius) than those obtained in the absence of ion exchange resin. Paclitaxel particle size was inversely correlated with the zeta potential of the fractional precipitation solution after the addition of ion exchange resin.
    Biotechnology and Bioprocess Engineering 10/2012; 17(5). DOI:10.1007/s12257-012-0056-8 · 1.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel simultaneous microwave-assisted extraction (MAE) and adsorbent treatment process was developed for recovering the anticancer agent paclitaxel from plant cell cultures and removing plant-derived tar and waxy compounds. The efficiency of the process was maximized by optimizing several major process variables. The optimal extraction time, ratio of adsorbent to liquid–liquid extract, ratio of methanol to biomass and extraction temperature were found to be 6 min, 4.5:1 (w/w), 1:1 (v/w) and 40 °C, respectively. By performing the simultaneous process under these conditions, we were able to recover most of the paclitaxel (>99%) with a purity of ∼22% after hexane precipitation. The efficiency of this process is similar to that of the conventional process (purity: ∼20%, yield: ∼95%) in which paclitaxel recovery is separate from adsorbent treatment. Therefore, it is expected that the conventional process can be simplified by simultaneously performing paclitaxel recovery and removal of impurities, thus dramatically reducing the cost of separation/purification.Graphical abstractHighlights► A simultaneous extraction-adsorbent treatment process is developed for paclitaxel. ► The purity and yield are 20% and 95%. ► The efficiency of this process is similar to that of the conventional process. ► The developed method can dramatically reduce the cost of separation/purification.
    Separation and Purification Technology 07/2011; 80(2):240-245. DOI:10.1016/j.seppur.2011.05.001 · 3.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we evaluated the efficiency and the behavior as well as shapes and sizes of paclitaxel precipitate as the surface area per working volume (S/V) of the reacting solution is increased in an acetone/pentane precipitation process for the purification of paclitaxel. The purity of paclitaxel after 24 h of precipitation was 54.0% when there was no surface area increase, while it was 54.2% and 77.7% when the surface area was increased by the use of glass beads and anion exchange resin (Amberlite IRA-400OH). The purity was significantly improved when Amberlite IRA-400OH is used as an agent to increase surface area. The yield of paclitaxel improved when glass beads were used but decreased when Amberlite IRA-400OH was used. Compared with the case where no surface area increasing agent was employed, the addition of glass beads or Amberlite IRA-400OH as a surface area increasing agent resulted in a considerable decrease in the size of the paclitaxel precipitate. When Amberlite IRA-400OH was added, the zeta potential value in the precipitation solution was higher (zeta potential value: −21.36 mV) than when no surface area increasing agent was employed (zeta potential value: −0.52 mV), indicating that the precipitated particles are much more stabilized with the addition of Amberlite IRA-400OH.
    Separation and Purification Technology 03/2012; 89:112–116. DOI:10.1016/j.seppur.2012.01.017 · 3.09 Impact Factor


5 Reads
Available from